Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma

  • End date
    Jul 30, 2023
  • participants needed
  • sponsor
    Shandong University
Updated on 30 January 2021


Endometrial Serous carcinoma (ESC) has similar molecular characteristics to high-grade serous ovarian carcinoma (HGSOC) and basal cell-like breast cancer, such as similar Chromosomal instability, somatic copy number variation profiles and somatic mutations. The clinical treatment of ESC also refers to the treatment model of HGSOC. The PARP inhibitor niraparib used in this study, which was approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy on March 27, 2017.

The homologous recombination related gene mutations in total endometrial cancer accounted for 22%. Homologous Recombination Repair Defect (HRD) +ARID1A accounted for 48%, and 53% of endometrial cancer cell lines were sensitive to PARP inhibitors. The incidence of HRD in endometrial cancer with high copy number (the pathological type is mainly ESC) is 50%, suggesting potential clinical applications of PARP inhibitors for the treatment of ESC.

Condition Endometrial Carcinoma, Serous cystadenocarcinoma, Uterine Cancer, Endometrial Cancer, papillary serous adenocarcinoma, serous adenocarcinoma, papillary serous cystadenocarcinoma
Treatment Niraparib
Clinical Study IdentifierNCT04716686
SponsorShandong University
Last Modified on30 January 2021


Yes No Not Sure

Inclusion Criteria

Women aged 18 or above
Histological confirmation of serous endometrial cancer or other types of endometrial cancer
ESC Patients have received at least 6 cycles of first-line platinum containing chemotherapy after surgery and achieved CR, PR or SD; ESC patients have received platinum containing chemotherapy after the first relapse and achieved CR, PR or SD; these two types of patients are enrolled in cohort 1 and receive niraparib alone as maintenance therapy within 12 weeks after the last chemotherapy treatment
ESC Patients have received >2 lines of platinum containing chemotherapy and relapsed; patients with other types of endometrial cancer have received >2 lines of platinum containing chemotherapy and have BRCA mutation or be defined as HRD positive; these 2 types of patients are enrolled in cohort 2 and receive niraparib monotherapy
Radiotherapy or endocrine therapy history is allowed
Cohort 1 life expectancy> 6 months; Cohort 2 life expectancy> 4 months
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Patients agreed to provide blood samples for testing BRCA status and HRR mutations
Patients agreed to provide formalin-fixed and paraffin-embedded tumor tissue samples for the detection of homologous recombination repair related genes (optional)
Laboratory criteria are as follows
Neutrophil count 1500/L;Platelets 100,000/L;Hemoglobin 10g/dL;Serum creatinine 1.5 times of the upper limit, or creatinine clearance 60mL/min;Total bilirubin 1.5 times of the upper limit or direct bilirubin 1.0 times of the upper limit;AST and ALT 2.5 times of the upper limit, and must be 5 times of the upper limit of when liver metastasis exists
Patients of reproductive potential must have a negative urinary or serum pregnancy test when done and promise to take effective contraceptive measuresduring the period of the study; Or without potential fertility, defined as
Women who have undergone contraceptive operation(hysterectomy, bilateral oophorectomy or bilateral salpingectomy), or
over 60 years old, or40 and <60 years of age, menopause for more than 12 months, and follicle-stimulating hormone test results are within the reference range of research institutions after menopause
Willingness to sign a written informed consent document and follow the plan
Any previous toxic and side effects of chemotherapy have recovered to CTCAE level 1 or baseline level, except for sensory neuropathy or hair loss with stable symptoms CTCAE level 2

Exclusion Criteria

Allergic to active or inactive ingredients of ZL-2306 (nirapali) or drugs with similar chemical structure to ZL-2306 (nirapali)
Stage Ia(on invasion to myometrium)
Symptomatic, uncontrollable brain metastases or pial metastases(No imaging scan is required); patients with spinal cord compression can still be considered for enrollment if they have received targeted therapy and have evidence of clinically SD for at least 28 days (patients with controlled central nervous system metastasis must have received radiotherapy or chemotherapy at least 1 month before and with no new symptoms related to central nervous system lesions or symptoms suggesting disease progression)
Received surgery within 3 weeks before the start of the study, or any surgical effects that have not recovered
Received palliative radiotherapy with >20% bone marrow 1 week before enrollment
Suffered from other aggressive cancers (except for fully treated basal or squamous cell skin cancer) within 2 years before enrollment
Previously or currently diagnosed as myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)
Suffer from serious or uncontrollable diseases, including but not limited to
Uncontrollable nausea and vomiting, inability to swallow drugs, any gastrointestinal diseases that may interfere with drug absorption and metabolism
Active viral infections such as human immunodeficiency virus, hepatitis B, hepatitis C, etc
Uncontrolled grand mal seizures, unstable spinal cord compression, superior vena cava syndrome, or other mental disorders
Immune deficiency (except for splenectomy)
Any past or current disease, treatment or laboratory abnormality that may interfere with the results of the study, or be defined as not suitable for this study
Receive platelet or red blood cell transfusion within 4 weeks before the start of the study
Pregnant or breastfeeding, or expect to become pregnant during the study
Have received any PARP inhibitor treatment previously
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note